Secukinumab reduces bone erosion and prevents enthesiophyte progression in psoriatic arthritis: Study Jacinthlyn Sylvia12 April 2025 1:45 AM ISTA new study published in the journal of Arthritis & Rheumatology found with high-resolution peripheral quantitative CT (HR-pQCT), that individuals...
Generate PMS data to assess patient safety : CDSCO Panel Tells Novartis Healthcare on additional indications of Secukinumab Dr. Divya Colin17 March 2025 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the drug major...
Secukinumab Reduces Psoriasis Itch and Restores Nerve Architecture, Study Finds Medha Baranwal27 Nov 2024 10:00 PM ISTGermany: A recent study, PSORITUS, revealed the efficacy of Secukinumab (SEC), a biologic therapy, in significantly reducing pruritus (itch)...
CDSCO Panel approves Novartis Healthcare for selective use of Secukinumab dose up to 300 mg Dr. Divya Colin14 July 2024 6:00 PM ISTNew Delhi: Reviewing the justification presented by the drug major Novartis Healthcare for the monoclonal antibody Secukinumab, the Subject Expert...
Secukinumab may significantly alleviate symptoms of psoriatic arthritis, finds research Dr Riya Dave24 April 2024 7:45 PM ISTResearchers have found that a dose of 300 mg of secukinumab can significantly alleviate symptoms of psoriatic arthritis (PsA) compared to placebo,...
Novartis wins USFDA nod for Cosentyx to treat hidradenitis suppurativa in adults Ruchika Sharma1 Nov 2023 2:00 PM ISTBasel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) to treat moderate to severe...
FDA approves first new biologic treatment option for hidradenitis suppurativa patients Dr. Kamal Kant Kohli1 Nov 2023 10:45 AM ISTThe US Food and Drug Administration (FDA) has approved secukinumab as first new biologic treatment option for moderate to severe hidradenitis...
CDSCO Panel approves Novartis proposal to update package insert of Secukinumab Dr. Divya Colin25 Oct 2023 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Center Drug Standard Control Organisation (CDSCO) has granted approval to drug...
FDA approves intravenous Secukinumab for Rheumatic diseases Dr. Kamal Kant Kohli11 Oct 2023 11:45 AM ISTThe US Food and Drug Administration (FDA) has approved an intravenous formulation of Secukinumab for patients with psoriatic arthritis, ankylosing...
Higher Levels Of Beta-Defensin 2 may Improve Clinical Response In Psoriatic Arthritis Patients Treated With Secukinumab Dr. Kamal Kant Kohli1 July 2023 8:00 PM ISTA recent study published in Rheumatic and Musculoskeletal Diseases has identified a potential biomarker that could help predict the response to...
Novartis Cosentyx gets European Commission nod for use in adults with hidradenitis suppurativa Ruchika Sharma1 Jun 2023 11:00 AM ISTA regulatory decision from the US Food and Drug Administration is expected later this year.
Secukinumab improves outcomes in active psoriatic arthritis patients: BMJ Jacinthlyn Sylvia17 May 2023 8:00 PM ISTImprovements in physical performance, health-related quality of life, and suppression of the development of structural damage were observed in...
